Abstract:DNA methylation, as an epigenetic mechanism, has a vital role in heart development. An increasing number of studies have investigated aberrant DNA methylation in pediatric or adult heart samples from patients with congenital heart defects (CHD). Placenta tissue, umbilical cord blood, or newborn blood have also been used to detect DNA methylation biomarkers for CHD. However, few studies have compared the methylation levels in fetal heart tissue with cardiac defects with that in normal controls. The present study conducted an integrative whole-genome and CpG site-specific DNA methylation analysis of fetal heart samples from 17 isolated cardiac defect cases, 14 non-isolated cardiac defect cases, and 22 controls with normal hearts, using methylated DNA immunoprecipitation microarray and MassARRAY EpiTYPER assays. Expression of genes adjacent to differentially methylated regions (DMRs) was measured by RT-qPCR and western blot analysis. The results revealed that fetuses with cardiac defects presented global hypomethylation. Genomic analysis of DMRs revealed that a proportion of DMRs were located in exons (12.4%), distal intergenic regions (11.14%), and introns (8.97%). Only 55.7% of DMRs were observed at promoter regions. Functional enrichment analysis for genes adjacent to these DMRs revealed that hypomethylated genes were involved in embryonic heart tube morphogenesis and immune-related regulation functions. Intergenic hypermethylation of EGFR and solute carrier family 19 member 1 (SLC19A1), and intragenic hypomethylation of NOTCH1 were validated in fetal heart tissues with cardiac defects. Only SLC19A1 expression was significantly decreased at the mRNA level, while EGFR, NOTCH1, and SLC19A1 expression were all significantly decreased at the protein level. In conclusion, the present study demonstrated that fetal cardiac defects may be associated with alterations in regional and single CpG site methylation outside of promoter regions, resulting in differentiated expression of corresponding genes associated with heart development. These results present new insights into the epigenetic mechanisms underlying abnormal heart development.

Research Progress in Modification of Histone Lysine Methylation and Congenital Heart Defect

[Research Progress on Genetic and Epigenetic Mechanisms in Congenital Heart Disease].

Heart failure: advanced development in genetics and epigenetics.

The Role of DNA Methylation in Syndromic and Non-Syndromic Congenital Heart Disease

Epigenetics and Congenital Heart Diseases

Advances in modulation of microRNA and DNA methylation in congenital heart diseases

Histone Deacetylases in Modulating Cardiac Disease and Their Clinical Translational and Therapeutic Implications

The interplay between DNA and histone methylation: molecular mechanisms and disease implications

The Research Advances in Epigenetic Mechanism of Embryonic-derived Diseases

Writing, erasing and reading histone lysine methylations

The spreading of facultative H3K9me3-heterochromatin drives congenital disease

The roles and mechanisms of epigenetic regulation in pathological myocardial remodeling

Histone modifications in Duchenne muscular dystrophy: pathogenesis insights and therapeutic implications

Acetylation in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications

Epigenetic regulation of heart failure

Histone Lysine Methyltransferase SETD2 Regulates Coronary Vascular Development in Embryonic Mouse Hearts

New insights into epigenetic modifications in heart failure.

Genome-wide Methylation Analysis Reveals Differentially Methylated CpG Sites and Altered Expression of Heart Development-Associated Genes in Fetuses with Cardiac Defects

Progresses on study of epigenetics in neurodegenerative disorders

[Progress in the Study of Histone Methyltransferases].

Genetic And Epigenetic Mechanisms In The Development Of Congenital Heart Diseases